Valeritas Holdings Inc

Valeritas — Investor Presentation (August 2017)

62 slides from Valeritas's investor presentation, Aug 16, 2017

  1. Slide 1: Investor Supplemental Presentation

    CONFIDENTIAL – AUTHORIZED USE ONLY I m p r o v i n g h e a l t h a n d s i m p l i f y i n g l i f e f o r p e o p l e w i t h d i a b e t e s Investor Supplemental Presentation August 2017

  2. Slide 2: Investor Supplemental Presentation Agenda

    2 Investor Supplemental Presentation Section Description Slide Diabetes Background 3 V-Go® Clinical Summary 14 Study Design & Quality Measures 46 V-Go Product Overview 51 Patient Satisfaction 58

  3. Slide 3: Diabetes Background

    CONFIDENTIAL – AUTHORIZED USE ONLY I m p r o v i n g h e a l t h a n d s i m p l i f y i n g l i f e f o r p e o p l e w i t h d i a b e t e s Diabetes Background August 2017

  4. Slide 4: Diabetes is a Global Epidemic & Healthcare Burden

    4 Diabetes is a Global Epidemic & Healthcare Burden Globally, diabetes is projected to increase 35% by 2040 It is estimated that 12% of global health expenditure is spent on diabetes AFR=Africa, EUR= Europe, MENA= Middle East and North Africa, NAC= North America and Caribbean, SACA=South and Central

  5. Slide 5: Primary Classifications of Diabetes

    5 Primary Classifications of Diabetes Type 1 Diabetes Type 2 Diabetes Age of onset Often diagnosed in children and young adults Usually diagnosed in adults Characteristics Insulin producing cells are destroyed by the body’s own immune system which results in insulin dependence Blood glucose levels r

  6. Slide 6: Failure to Intensify Insulin and Poor Adherence Can Make Therapy Ineffective

    6 Failure to Intensify Insulin and Poor Adherence Can Make the Most Efficacious Diabetes Therapy Ineffective <7% >7% or <8% ≥8% or <9% >9% 20.4% 26.5% 20.4% 32.7% P e rce n t of P ati e n ts A1C Range 80% Not at Goal Grabner et al. ClinicoEconomics and Outcomes Research. 2013:5 471–479 and Chen Y et

  7. Slide 7: Pathophysiology of Diabetes

    7 Pathophysiology of Diabetes Digestion converts food into glucose Glucose enters the bloodstream The pancreas makes little (T2DM) or no insulin (T1DM) Little or no insulin enters the bloodstream Glucose builds up in the bloodstream 1 2 3 4 5 Adapted from "Diabetes Pictures: Type 2 Diabetes Symptoms

  8. Slide 8: A1C as a Measurement of Glycemic Control

    8 A1C as a Measurement of Glycemic Control ▫ An A1C test is a blood test used to diagnose diabetes and assess how well someone is managing their diabetes. – The value is reflected as a percentage and reflects average blood glucose over the past 2 to 3 months and has strong predictive value for compl

  9. Slide 9: Assessment of Glycemic Control in Diabetes

    9 Assessment of Glycemic Control in Diabetes 1. ADA Standards of Care 2017. 2. "Report Cards." Diabetes Care. NCQA, 2016. Web. 25 May 2017. <http://www.ncqa.org/report-cards/health- plans/state-of-health-care-quality/2016-table-of-contents/diabetes-care>. Reported achievement from 2015. 3. Stratton

  10. Slide 10: Strong Need and Opportunity for V-Go

    10 Strong Need and Opportunity for V-Go® A1C Considerations 2015 Report Card2 Commercial PPO Medicare PPO < 7% A reasonable A1C goal for many non- pregnant adults1 67% Did not Achieve Not applicable* < 8% Appropriate for some patients including those with long-standing diabetes in whom the goal is d

  11. Slide 11: Better Glycemic Control Improves and Extends Lives

    11 Better Glycemic Control Improves and Extends Lives Significant Adverse Health Effects Influenced by Poor Glycemic Control Stratton IM et al. BMJ. 2000;321:405-412. 21% Deaths from Diabetes 14% Heart Attacks 37% Microvascular Complications 43% Peripheral Vascular Disease Each 1% reduction in mean

  12. Slide 12: Most Patients will Eventually Require Insulin Therapy

    12 Most Patients will Eventually Require Insulin Therapy The UKPDS found that more than half of newly diagnosed people with type 2 diabetes (T2DM) will require insulin initiation within 6 years of starting other antidiabetic therapies.1 1. Wright A et al. Diabetes Care 2002; 25: 330–336. 2. Graphic

  13. Slide 13: Continuous Delivery of a Basal Rate of Insulin Provides Improved Insulin Profiles

    13 Continuous Delivery of a Basal Rate of Insulin Provides Improved Insulin Profiles Cross over study in 21 patients with T2DM comparing equal doses (mean 26 U) of continuous basal subQ infusion (CSII) of rapid-acting insulin (RAI) to once daily subQ of insulin glargine (IG) Injection of IG Continuo

  14. Slide 14: V-Go Clinical Summary

    I m p r o v i n g h e a l t h a n d s i m p l i f y i n g l i f e f o r p e o p l e w i t h d i a b e t e s V-Go® Clinical Summary August 2017

  15. Slide 15: Forward Looking Statements

    15 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities. Any sale by the company shall be made pursuant to a definitive purchase agreement. Unless otherwise stated in this presentation, references to “Valer

  16. Slide 16: $16.5 Billion Annual Opportunity

    16 1. Based on V-Go® Wholesale Acquisition Price (WAC) of $306.70 per month x 12 months x 4.5M Patients with Type 2 Diabetes on Insulin not at goal. WAC price is the gross price sold to wholesalers, and does not take into account fees, discount and rebates charged to the company. 2. Holman RR et al.

  17. Slide 17: Patients May Need Basal and Mealtime Insulin

    17 Patients with Diabetes may need Basal and Mealtime Insulin to Achieve or Maintain Glycemic Control 100 140 180 260 220 Mean 24- hour CGM sensor glucose profiles1 Breakfast Lunch Dinner G lu co se ( m g /d l) Overnight Basal insulin has a flat insulin profiles and is not designed to cover glucose

  18. Slide 18: Goal of Insulin Therapy: Mimic Physiologic Insulin Secretion

    18 Goal of Insulin Therapy Mimic Physiologic Insulin Secretion Mean Plasma Levels of Insulin During 24-Hour Period1 1. Polonsky KS, et al. N Engl J Med. 1988;318(19):1231-1239. 2. Holman RR et al. N Engl J Med. 2009 Oct 29;361(18):1736-47. Without diabetes With type 2 diabetes ~82% of Patients with

  19. Slide 19: Non-adherence to Insulin is Associated with Poor Glycemic Control

    19 Non-adherence to Insulin is Associated with Poor Glycemic Control1 1. Donnelly L et al. Q J Medicine 2007:100;345-350. 2. Peyrot M et al. Diabetes Care 2010:33;240-245. 3. Peyrot M et al. Diabet Med. 2012:May;29(5): 682-689. 4. Yavuz D et al. Patient Preference and Adherence. 2015:9; 225-231. 5.

  20. Slide 20: V-Go Addresses Physicians' Greatest Concerns Regarding MDI

    20 V-Go® Addresses Physicians’ Greatest Concerns Regarding Challenges Patients with T2DM Face on MDI Based on market research conducted in October, 2016, n=102, Doctors ranked their Top 5 Challenges and separately the Greatest Benefits from V-Go Highest Rated Benefits from V-Go Greatest Challenges t

  21. Slide 21: Insulin works if the Patient Takes it as Prescribed

    21 Insulin works……..if the Patient Takes it as Prescribed Complex regimen Inconvenient to dose Too many injections Decreases Adherence Barriers to Multiple Daily Injections When taken, insulin is the most potent agent available to treat hyperglycemia1 Pain/anxiety to inject Basal-Bolus therapy with

  22. Slide 22: Simplify Basal-Bolus Insulin Therapy with V-Go

    22 Simplify Basal-Bolus Insulin Therapy with V-Go® Conceptual depiction of basal-bolus therapy delivery options © 2017, Valeritas, Inc. Basal-Bolus therapy with MDI requires a long or intermediate acting insulin plus a short or rapid acting insulin and typically 4 injections/day. Basal-Bolus therapy

  23. Slide 23: Strong and Extensive Data Supports Broad Adoption of V-Go

    23 1. Rosenfeld CR, et al. Endocr Pract. 2012; 18 (5):660-667. 2. Grunberger, G, et al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 985-P. 3. Omer, A. et al. Poster presented at 73rd Scientific Sessions of the ADA; 2013 June 21-25; Chicago, IL. 980-P. 4. La

  24. Slide 24: Robust Clinical Data Validates V-Go A1C Reductions with Less Insulin

    24 Robust Clinical Data Validates the Ability of V-Go® to Deliver Clinically Relevant Reductions in A1C with Less Insulin UPP7 UMASS8 8.8% N=23 3 months 10.7% N=14 3 months -0.9 [VALUE]* [VALUE]* -1.4 -1.6 [VALUE] -1.2 -2.4 -1.6 9.7% N= 83 ~ 5 months VALIDATE 13 9.6% N=204 ~ 7 months C h an ge in A

  25. Slide 25: Patients Switched to V-Go Lowered A1C with ~55 Units/Day

    25 Regardless of Insulin Starting Point, Patients Switched to V-Go® Significantly Lowered their A1C with ~55 Units/Day V-Go has consistently shown improvements in A1C using less insulin Total Daily Insulin Doses Prescribed Before V-Go ( U/Day) Across Multiple Studies Study UPP6 SIMPLE1 EVIDENT3 Ray8

  26. Slide 26: V-Go Improves Glycemic Control and Reduces Prescribed Insulin

    26 V-Go® Insulin Delivery Improves Glycemic Control and Reduces Prescribed Insulin Fasting Plasma Glucose (FPG) reductions based on patients with baseline FPG measurements and corresponding basal insulin dosage (n=67). A1C reductions based on patients on insulin at baseline (n=180) compared to V-Go

  27. Slide 27: Healthcore Study: V-Go Improved A1C with Less Insulin

    27 Prospective Study Conducted by Healthcore Inc.(1) Demonstrated V-Go® Improved A1C with Less Insulin V-Go n=169 STO n=246 -0.95* -0.46* C ha n ge in A1 C *Significant compared to baseline, Significant between groups Baseline A1C (%): V-Go 9.88 and STO 9.34 Baseline total daily insulin dose (u/da

  28. Slide 28: Clinical Benefits When Switched from Basal-Bolus (MDI)

    28 V-Go® Demonstrated Clinical Benefits in Patients with T2DM when Switched from Basal-Bolus (MDI) Baseline On V-Go 115 [VALUE]* In su lin TD D ( u n its ) [VALU E]* Cha n ge in A1 C Switched from Basal-Bolus (MDI) Baseline 9.3% n=70 (all patients with two follow-up A1C values for a mean duration of

  29. Slide 29: Clinical Benefits When Switched from Basal Insulin

    29 V-Go® Demonstrated Clinical Benefits in Patients with T2DM when Switched from a Basal Insulin Regimen Baseline On V-Go 55 54 In su lin TD D ( u n its ) [VALU E]* Cha n ge in A1 C Switched from Basal Insulin Baseline 9.5% n=47 (all patients with two follow-up A1C values for a mean duration of 7 mo

  30. Slide 30: Clinical Benefits Across All Types of Diabetes

    30 V-Go® Demonstrates Clinical Benefits Across All Types of Diabetes -1.53* -1.61* -1.03* -1.79* -1.83* -1.52* LSM Cha n ge in A1 C Baseline: 98 U V-Go: 59 U* Baseline: 104 U V-Go: 51 U* Mean Insulin TDD† Baseline: 99 U V-Go: 58 U* Lajara R, et al. Diabetes Therapy. 2015 and data on file *p<0.001 co

  31. Slide 31: Improved A1C Control Regardless of Baseline Insulin Dosing

    31 V-Go® Improved A1C Control Regardless of Baseline Insulin Dosing -1.5* -1.7* Cha n ge in A1 C < 100 U/day at Baseline ≥ 100 U/day at Baseline Baseline 9.3% Baseline 9.5% 62 143 54† 67* In su lin TD D (U/d ay ) Baseline Baseline On-V-Go On V-Go < 100 U/day at Baseline ≥ 100 U/day at Baseline After

  32. Slide 32: Clinical and Economic Benefits in a High-Risk Population

    32 Switching to V-Go® Resulted in Clinical and Economic Benefits in a High-Risk Population Cha n ge in A1C N=97 All patients were previously on basal (37%) or basal-bolus (63%) insulin injections *p<0.001 at 3 months compared to baseline †Savings are based on WAC pricing and calculated from subtract

  33. Slide 33: Large Real-World Analysis: Improved Control with Less Insulin

    33 Results from a Large Real-World Analysis Showed V-Go® Improved Glycemic Control with Less Insulin 9.63 8.04 7.79 4 5 6 7 8 9 10 11 12 13 14 D is trib u tio n o f Patien ts A1C (%) Baseline (n=204) 14 Weeks (n=204) 27 Weeks (n=137) A1C data are arithmetic means at baseline (week 0) compared to fir

  34. Slide 34: Greater Improvements in Glycemic Control vs MDI

    34 7.7* 7.6* 8.4* 8.1* 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 Baseline 12 week 27 week A 1C ( % ) V-Go: N=56 BL A1C- 9.5% BL TDD - 51 U/day, Starting V-Go TDD- 52 U/day, 12 week TDD- 56 U/day, 27 week TDD- 56 U/day MDI: N=60 BL A1C- 9.4%, BL TDD- 46 U/day, Starting MDI TDD- 64 U/day, 12 week TDD- 75 U/day

  35. Slide 35: V-Go More Cost-Effective Than MDI for Basal-Bolus Therapy

    35 *p<0.001 compared to baseline †p-value calculated using a mixed model to determine least squares mean change from baseline between group difference -1.98* -1.34* LSM Ch a nge in A 1 C a t 2 7 w e e k s -0.64% †p=0.020 V-Go® is More Cost-Effective for Basal-Bolus Therapy Compared to Multiple Daily

  36. Slide 36: Patients Intensified from Basal Required Less Insulin vs MDI

    36 51 56 56† 46 75* 78* Baseline 12 weeks 27 weeks In su lin TD D ( U/ d ay ) V-Go MDI 90 80 70 60 50 40 30 0 Patients Intensified to Basal-Bolus from Basal Insulin Required Less Insulin with V-Go® vs MDI N=116 MDI=Multiple Daily Injections *p<0.001 vs baseline. †p<0.0001 vs MDI at 27 weeks Lajara R

  37. Slide 37: EVIDENT: Improvements in A1C and Reductions in Insulin

    37 Mean TD D ( U/ d ay ) 20 40 60 80 67 Pre V-Go On V-Go Insulin TDD Utilization -2.0 -1.5 -1.0 -0.5 0.0 [VALUE] * [VALUE] * Mean C h an ge in A1 C 15 Weeks 34 weeks Change in A1C 15 Weeks 34 weeks Baseline Range (10 to 200 U) [VALU E]† [VALU E]† 62 Insulin Delivery with V-Go® Demonstrated Improveme

  38. Slide 38: Patients on 2+ Injections/Day Switching to V-Go

    38 Mean TD D ( U/ d ay ) 20 40 60 80 72 Pre V-Go On V-Go Insulin TDD Utilization -2.0 -1.5 -1.0 -0.5 0.0 [VALUE]* [VALUE]* Mean C h an ge in A1 C 15 Weeks 34 weeks Change in A1C 15 Weeks 34 weeks Baseline Range (20 to 200 U) [VALU E]* [VALU E]* [VALU E]† In Patients on ≥ 2 Insulin Injections/Day Swi

  39. Slide 39: Improved A1C Control Regardless of Baseline Insulin Dosing

    39 ≤ 50 U at Baseline Basal to Bolus Ratio: 83% to 17% 51 to 75 U at Baseline Basal to Bolus Ratio: 69% to 31% > 75 U at Baseline Basal to Bolus Ratio: 60% to 40% + 14 U/day* 37.4 to 51.6 U/day Basal to Bolus Ratio: 54% to 46% - 3 U/day 62.5 to 59.3 U/day Basal to Bolus Ratio: 54% to 46% - 23 U/day*

  40. Slide 40: Glycemic Targets Achieved in Majority of Patients

    40 Glycemic Targets Achieved in the Majority of Patients with V-Go® using Less Insulin A sub analysis to evaluate the % of patients with uncontrolled type 2 diabetes (A1C > 8%) who achieved an A1C < 8% and/or a reduction in A1C of ≥ 1% after being switched from conventional insulin delivery (syringe

  41. Slide 41: Patients Prescribed MDI Clinically Benefited Switching to V-Go

    41 On MDI On V-Go 58 [VAL UE]* Patients Prescribed MDI for Insulin Delivery Clinically Benefited when Switching to V-Go® Basal Insulin Prandial Insulin Total Daily Dose 20 40 60 80 100 120 On MDI On V-Go 108 [VAL UE]* Insu lin ( U n it s/d ay ) On MDI On V-Go 50 [VAL UE]* 7.0 8.0 9.0 10.0 On MDI On

  42. Slide 42: In 66% of Patients A1C Improved and Insulin Reduced

    42 In 66% of Patients Both A1C Improved and Insulin was Reduced when Switched from MDI to V-Go® 66% 11% 2% 21% N=86 patients, each dot represents a patient Relationship between Change in A1C and Change in TDD on V-Go Lajara R, et al. Poster presented at the 22nd Annual ISPOR Meeting, May 2017; Bosto

  43. Slide 43: Switching from MDI to V-Go Resulted in Pharmacy Cost Savings

    43 Switching Patients from MDI to V-Go® Resulted in a Direct Pharmacy Cost Savings to the Plan Direct Pharmacy Costs Per Patient Per Month (PPPM) On MDI N=86 On V-Go N=86 Prescribed insulin costs PPPM $888.00 $471.00 Pen needles/syringes/V-Go costs PPPM $37.00 $308.00† Total insulin therapy costs PP

  44. Slide 44: V-Go Significantly Reduced A1C with Less Insulin (UMASS)

    44 6.0 7.0 8.0 9.0 10.0 11.0 Pre V-Go On V-Go 10.7 8.3* A1C (% ) 0 20 40 60 80 100 120 140 Pre V-Go On V-Go 119 64† In su lin TD D ( u n its ) N=14 Average Duration = 88 days †p=0.01, *p=0.001 1Based on Insulin TDD absolute units Change -2.4 V-Go® Significantly Reduced A1C with Less Insulin Key Bene

  45. Slide 45: Glycemic Control Deteriorated After V-Go Discontinued

    45 Glycemic Control Improved with V-Go® using Less Insulin and Deteriorated after V-Go was Discontinued Rosenfeld CR, et al. Endocr Pract. 2012. Before V-Go With V-Go After Discontinuing V-Go 8.8 7.6* 8.2† A1C (% ) N=23 A1C- *p=0.002 vs “Before V-Go”, †p=0.011 vs “With V-Go” This V-Go study was cond

  46. Slide 46: Study Design & Quality Measures

    I m p r o v i n g h e a l t h a n d s i m p l i f y i n g l i f e f o r p e o p l e w i t h d i a b e t e s Study Design & Quality Measures August 2017

  47. Slide 47: Real World Evidence Demonstrates Real Results

    47 Real World Evidence Demonstrates Real Results • Valeritas has focused on providing data that demonstrates clinical and economic benefits in a real-world setting • Based on standard clinical practice • Inclusive of a wide range of patients (good control to poor control) • No forced insulin titrati

  48. Slide 48: Randomized Controlled Trials vs Real World Evidence

    48 Randomized Controlled Trials vs Real World Evidence • Prospective in design • Required for FDA submissions of pharmaceuticals, not devices • Tests a pre-conceived hypothesis that may or may not be based on previous scientific observations • Strict criteria for subjects studied; “sterile environme

  49. Slide 49: Disparity Between RCTs and Real World Clinical Practice

    49 Disparity May Exist between Randomized Controlled Trials (RCTs) and Real World Clinical Practice 0 20 40 60 80 100 RCT "Controlled Environment" n=2,975 EMR "Real World" n=12,562 [VALUE]% [VALUE]% A1 C T ar ge t A ch ie ve d Blonde L et al. Diabetes 2014;63(Supp 1):A235 RCTs follow restrictive/con

  50. Slide 50: A Changing Healthcare Landscape: Quality Measures

    50 A Changing Healthcare Landscape Quality Measures and Performance Standards • Health plans and physicians are being called on to close gaps in care and improve overall quality • “Quality of Diabetes Care” is measured across all performance standards • The Centers for Medicare and Medicaid (CMS) us

  51. Slide 51: V-Go Product Overview

    CONFIDENTIAL – AUTHORIZED USE ONLY I m p r o v i n g h e a l t h a n d s i m p l i f y i n g l i f e f o r p e o p l e w i t h d i a b e t e s V-Go® Product Overview August 2017

  52. Slide 52: Forward Looking Statements

    52 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities. Any sale by the company shall be made pursuant to a definitive purchase agreement. Unless otherwise stated in this presentation, references to “Valer

  53. Slide 53: V-Go Designed for Patient Ease of Use with Commercial Scale Manufacturing

    53 V-Go® is Designed for Patient Ease of Use with High Quality Commercial Scale Manufacturing V-Go Device Overview • Simple filling does not require calculations, measuring or needles • Prevents accidental needle sticks V-Go® EZ FILLTM Bolus Chamber Insulin Fluid Fluid Basal Chamber Piston Needle 24

  54. Slide 54: Continuous and Consistent Basal Rate: Flow Rate Study

    54 Time (min) R at e (U n its/hr ) 0.00 0.41 0.82 1.23 1.64 2.05 0 60 120 180 240 300 360 420 480 540 600 660 720 2. 8 1. 6 1. 5 0. 3 0. 2 0. 0 Continuous and Consistent Basal Rate: Flow Rate Study of V-Go® 30 Units/Day* V-Go® Instructions for Patient Use. Valeritas, Inc. 2011. = V-Go 30 = Specifica

  55. Slide 55: V-Go Combines Simplicity and Physiologic Insulin

    55 V-Go® Combines Simplicity and Physiologic Insulin in Patient-Friendly and Easy-to-Use Wearable Device Press button to insert needle and start basal rate of insulin delivered at a constant rate Deliver on-demand insulin for mealtime coverage in 2 units/click Bolus Delivery Button Activate Bolus Re

  56. Slide 56: Training Patients on V-Go

    56 Training Patients on V-Go® For a more detailed review, see the multimedia resources at www.vgostart.com You, Your Staff, or a Valeritas Representative can easily train the patient FILL WEAR GO Fill, Wear & Go…

  57. Slide 57: V-Go Filling Process

    57 V-Go® Filling Process Requires no syringes, measuring or calculating….. V-Go is filled with a single type of insulin, a U-100 fast-acting insulin (also referred to as a rapid acting insulin). Humalog® (insulin lispro, rDNA origin) and NovoLog® (insulin aspart, rDNA origin) have been tested by Val

  58. Slide 58: Patient Satisfaction

    I m p r o v i n g h e a l t h a n d s i m p l i f y i n g l i f e f o r p e o p l e w i t h d i a b e t e s Patient Satisfaction August 2017

  59. Slide 59: Forward Looking Statements

    59 Forward Looking Statements This presentation shall not be deemed an offer to sell securities nor a solicitation of an offer to purchase securities. Any sale by the company shall be made pursuant to a definitive purchase agreement. Unless otherwise stated in this presentation, references to “Valer

  60. Slide 60: Patients Rated Convenience and Quality of Life as Improved

    60 0% 10% 20% 30% 40% 50% 60% 70% 80% Prior Therapy V-Go Therapy 28% 27% 10% 53% Su rv ey R e sp o n d e n ts Convenience Very Convenient Somewhat Convenient Patients Rated the Convenience of V-Go® and Their Quality of Life as Improved vs. Previous Therapies Data on File Opportunistic Copay Card, V-

  61. Slide 61: V-Go Patient Feedback is Very Strong

    61 V-Go® Patient Feedback is Very Strong Extremely Satisfied = 38% Very Satisfied= 35% Satisfied= 16% Somewhat Satisfied= 7% Not Satisfied=5% >90% of Patients are Satisfied with the Ease of Using V-Go Extremely Satisfied = 39% Very Satisfied= 32% Satisfied= 16% Somewhat Satisfied= 7% Not Satisfied=6

  62. Slide 62: Patients on V-Go See Improved Control and High Compliance

    62 Patients on V-Go® See Improved Control, Have a Positive Experience and Achieve High Compliance 53% 36% 7% 3% 1% Very positive Positive Neutral Negative ~ 90% of V-Go Users have a Very positive/Positive Impression of V-Go* 0% 10% 20% 30% 40% 50% Greatly improved Slightly improved Remained the same

Valeritas Holdings — Investor Presentation (August 2017) on 6ix